Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 2
1986 1
1990 1
1994 1
1996 1
2000 2
2001 1
2002 2
2003 2
2004 1
2007 1
2009 1
2010 1
2011 7
2015 6
2016 3
2017 1
2018 2
2019 2
2020 2
2021 4
2022 2
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Gordon KB, et al. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. N Engl J Med. 2016. PMID: 27299809 Free article. Clinical Trial.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K; IXORA-R Study Group. Blauvelt A, et al. Among authors: guenther lc. Br J Dermatol. 2021 Jun;184(6):1047-1058. doi: 10.1111/bjd.19509. Epub 2020 Oct 25. Br J Dermatol. 2021. PMID: 32880909 Free PMC article. Clinical Trial.
Cyclosporin A.
Page EH, Wexler DM, Guenther LC. Page EH, et al. Among authors: guenther lc. J Am Acad Dermatol. 1986 May;14(5 Pt 1):785-91. doi: 10.1016/s0190-9622(86)70094-7. J Am Acad Dermatol. 1986. PMID: 3519696 Review.
Acitretin Use in Dermatology.
Guenther LC, Kunynetz R, Lynde CW, Sibbald RG, Toole J, Vender R, Zip C. Guenther LC, et al. J Cutan Med Surg. 2017 Nov/Dec;21(3_suppl):2S-12S. doi: 10.1177/1203475417733414. Epub 2017 Sep 27. J Cutan Med Surg. 2017. PMID: 28952335 Review.
Treating to Target(s) With Interleukin-17 Inhibitors.
Lynde CW, Beecker J, Dutz J, Flanagan C, Guenther LC, Gulliver W, Papp K, Rahman P, Sholter D, Searles GE. Lynde CW, et al. Among authors: guenther lc. J Cutan Med Surg. 2019 Mar/Apr;23(2_suppl):3S-34S. doi: 10.1177/1203475418824565. Epub 2019 Feb 11. J Cutan Med Surg. 2019. PMID: 30742778 Review.
Inherited disorders of complement.
Guenther LC. Guenther LC. J Am Acad Dermatol. 1983 Dec;9(6):815-39. doi: 10.1016/s0190-9622(83)70195-7. J Am Acad Dermatol. 1983. PMID: 6315788 Review.
Fixed-dose combination therapy for psoriasis.
Guenther LC. Guenther LC. Am J Clin Dermatol. 2004;5(2):71-7. doi: 10.2165/00128071-200405020-00001. Am J Clin Dermatol. 2004. PMID: 15109271 Review.
Optimizing treatment with topical tazarotene.
Guenther LC. Guenther LC. Am J Clin Dermatol. 2003;4(3):197-202. doi: 10.2165/00128071-200304030-00006. Am J Clin Dermatol. 2003. PMID: 12627995 Review.
46 results